Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine.
Identifieur interne : 006702 ( Main/Exploration ); précédent : 006701; suivant : 006703Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine.
Auteurs : Yasuko Tsunetsugu-Yokota [Japon] ; Kazuo Ohnishi ; Toshitada TakemoriSource :
- Reviews in medical virology [ 1052-9276 ]
Descripteurs français
- KwdFr :
- Animaux, Anticorps monoclonaux (immunologie), Anticorps monoclonaux (usage thérapeutique), Humains, Immunothérapie (), Modèles animaux de maladie humaine, Protéines virales (immunologie), Souris, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Vaccins antiviraux (immunologie), Vaccins antiviraux (pharmacologie), Virus du SRAS (immunologie).
- MESH :
- immunologie : Anticorps monoclonaux, Protéines virales, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Virus du SRAS.
- pharmacologie : Vaccins antiviraux.
- usage thérapeutique : Anticorps monoclonaux.
- Animaux, Humains, Immunothérapie, Modèles animaux de maladie humaine, Souris, Syndrome respiratoire aigu sévère.
English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (immunology), Antibodies, Monoclonal (therapeutic use), Disease Models, Animal, Humans, Immunotherapy (methods), Mice, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (therapy), Viral Proteins (immunology), Viral Vaccines (immunology), Viral Vaccines (pharmacology).
- MESH :
- chemical , immunology : Antibodies, Monoclonal, Viral Proteins, Viral Vaccines.
- chemical , pharmacology : Viral Vaccines.
- chemical , therapeutic use : Antibodies, Monoclonal.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- methods : Immunotherapy.
- therapy : Severe Acute Respiratory Syndrome.
- Animals, Disease Models, Animal, Humans, Mice.
Abstract
SARS-CoV is a new type of human coronavirus identified as a causative agent of severe acute respiratory syndrome (SARS). On the occasion of the SARS outbreak, various monoclonal antibodies (mAbs) against SARS-CoV have been developed and applied for diagnosis, clinical management and basic research. In this review, we overview the biochemical and functional properties and applications of these SARS-CoV mAbs. We also focus on a variety of vaccines currently under development and discuss the immune response elicited by these vaccines in animal models, hopefully to better understand what we need to do next to fight against newly emerging pathogens in the future.
DOI: 10.1002/rmv.492
PubMed: 16518829
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002320
- to stream PubMed, to step Curation: 002320
- to stream PubMed, to step Checkpoint: 003511
- to stream Ncbi, to step Merge: 001409
- to stream Ncbi, to step Curation: 001409
- to stream Ncbi, to step Checkpoint: 001409
- to stream Main, to step Merge: 006C20
- to stream Main, to step Curation: 006702
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine.</title><author><name sortKey="Tsunetsugu Yokota, Yasuko" sort="Tsunetsugu Yokota, Yasuko" uniqKey="Tsunetsugu Yokota Y" first="Yasuko" last="Tsunetsugu-Yokota">Yasuko Tsunetsugu-Yokota</name><affiliation wicri:level="3"><nlm:affiliation>Department of Immunology, National Institute of Infectious Diseases, Toyama-cho, Shinjuku-ku, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Immunology, National Institute of Infectious Diseases, Toyama-cho, Shinjuku-ku, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Ohnishi, Kazuo" sort="Ohnishi, Kazuo" uniqKey="Ohnishi K" first="Kazuo" last="Ohnishi">Kazuo Ohnishi</name></author><author><name sortKey="Takemori, Toshitada" sort="Takemori, Toshitada" uniqKey="Takemori T" first="Toshitada" last="Takemori">Toshitada Takemori</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2006 Mar-Apr</MedlineDate></PubDate></date><idno type="RBID">pubmed:16518829</idno><idno type="pmid">16518829</idno><idno type="doi">10.1002/rmv.492</idno><idno type="wicri:Area/PubMed/Corpus">002320</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002320</idno><idno type="wicri:Area/PubMed/Curation">002320</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002320</idno><idno type="wicri:Area/PubMed/Checkpoint">003511</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003511</idno><idno type="wicri:Area/Ncbi/Merge">001409</idno><idno type="wicri:Area/Ncbi/Curation">001409</idno><idno type="wicri:Area/Ncbi/Checkpoint">001409</idno><idno type="wicri:doubleKey">1052-9276::Tsunetsugu Yokota Y:severe:acute:respiratory</idno><idno type="wicri:Area/Main/Merge">006C20</idno><idno type="wicri:Area/Main/Curation">006702</idno><idno type="wicri:Area/Main/Exploration">006702</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine.</title><author><name sortKey="Tsunetsugu Yokota, Yasuko" sort="Tsunetsugu Yokota, Yasuko" uniqKey="Tsunetsugu Yokota Y" first="Yasuko" last="Tsunetsugu-Yokota">Yasuko Tsunetsugu-Yokota</name><affiliation wicri:level="3"><nlm:affiliation>Department of Immunology, National Institute of Infectious Diseases, Toyama-cho, Shinjuku-ku, Tokyo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Immunology, National Institute of Infectious Diseases, Toyama-cho, Shinjuku-ku, Tokyo</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Ohnishi, Kazuo" sort="Ohnishi, Kazuo" uniqKey="Ohnishi K" first="Kazuo" last="Ohnishi">Kazuo Ohnishi</name></author><author><name sortKey="Takemori, Toshitada" sort="Takemori, Toshitada" uniqKey="Takemori T" first="Toshitada" last="Takemori">Toshitada Takemori</name></author></analytic><series><title level="j">Reviews in medical virology</title><idno type="ISSN">1052-9276</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (immunology)</term><term>Antibodies, Monoclonal (therapeutic use)</term><term>Disease Models, Animal</term><term>Humans</term><term>Immunotherapy (methods)</term><term>Mice</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (therapy)</term><term>Viral Proteins (immunology)</term><term>Viral Vaccines (immunology)</term><term>Viral Vaccines (pharmacology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps monoclonaux (immunologie)</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Humains</term><term>Immunothérapie ()</term><term>Modèles animaux de maladie humaine</term><term>Protéines virales (immunologie)</term><term>Souris</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins antiviraux (pharmacologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Viral Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Protéines virales</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunotherapy</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Humans</term><term>Mice</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Immunothérapie</term><term>Modèles animaux de maladie humaine</term><term>Souris</term><term>Syndrome respiratoire aigu sévère</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">SARS-CoV is a new type of human coronavirus identified as a causative agent of severe acute respiratory syndrome (SARS). On the occasion of the SARS outbreak, various monoclonal antibodies (mAbs) against SARS-CoV have been developed and applied for diagnosis, clinical management and basic research. In this review, we overview the biochemical and functional properties and applications of these SARS-CoV mAbs. We also focus on a variety of vaccines currently under development and discuss the immune response elicited by these vaccines in animal models, hopefully to better understand what we need to do next to fight against newly emerging pathogens in the future.</div></front></TEI><affiliations><list><country><li>Japon</li></country><region><li>Région de Kantō</li></region><settlement><li>Tokyo</li></settlement></list><tree><noCountry><name sortKey="Ohnishi, Kazuo" sort="Ohnishi, Kazuo" uniqKey="Ohnishi K" first="Kazuo" last="Ohnishi">Kazuo Ohnishi</name><name sortKey="Takemori, Toshitada" sort="Takemori, Toshitada" uniqKey="Takemori T" first="Toshitada" last="Takemori">Toshitada Takemori</name></noCountry><country name="Japon"><region name="Région de Kantō"><name sortKey="Tsunetsugu Yokota, Yasuko" sort="Tsunetsugu Yokota, Yasuko" uniqKey="Tsunetsugu Yokota Y" first="Yasuko" last="Tsunetsugu-Yokota">Yasuko Tsunetsugu-Yokota</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006702 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006702 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16518829
|texte= Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16518829" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |